CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure

Stock News

08/07

CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.

On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.

Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on CARSGEN-B's proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1163799508"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163799508\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163799508?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163799508","market":"fut","top_or_hot":-1,"title":"CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure","media":"Stock News","content":"<p><b>CARSGEN-B</b> (<b>02171</b>) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.<br><br>On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.<br><br>Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on <b>CARSGEN-B</b>'s proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-07 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CARSGEN-B</b> (<b>02171</b>) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.<br><br>On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.<br><br>Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on <b>CARSGEN-B</b>'s proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1163799508","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163799508","pubTimestamp":1786071162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.On...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","KCAI":"KraneShares China Alpha Index ETF","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","BK1585":"昨日强势股","02171":"科济药业-B"},"translate_title":"CARSGEN-B (02171) 飙升超过 4%，CT1190B 在二线失败后获得 IND Nod 用于 R/R LBCL 患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1,"VXUS":1,"KCAI":1},"content_text":"CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on CARSGEN-B's proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}